drugset / Trial / NCT07378046

The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster

NCT07378046

Recruiting 750 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of muscle relaxant, which can relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. Therefore, investigators hypothesize that baclofen may effectively reduce the severity of HZ pain without significantly increasing adverse events.

Timeline

Start
2025-12-15
Primary completion
2027-09-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Baclofen Small molecule 15 mg Oral

Indications